A Randomized Trial of Selumetinib and Olaparib or Selumetinib Alone in Patients with Recurrent or Persistent RAS Pathway Mutant Ovarian and Endometrial Cancers: A ComboMATCH Treatment Trial
NRG EAY191-N4
Description
This study is looking for patients with recurrent or persistent ovarian or endometrial cancer, and has a change in the gene family called RAS genes. Patients will either get the drugs selumetinib and olaparib or the drug selumetinib alone.
Protocol#: NRG-EAY191-N4
Study Information
Age Group: Adults
Participating Sites: Sanford Bismarck Region; Sanford Fargo Region; Sanford Sioux Falls Region
Scope:
Phase: II
Participating Sites: Sanford Bismarck Region; Sanford Fargo Region; Sanford Sioux Falls Region
Scope:
Phase: II
Principal Investigator(s)
Maria Bell
Department
Management Group:
Gynecologic - Oncology; NCORP
NCT:
NCT05554328
Contact Us
For more information on clinical trials at Sanford Health, call one of our regional clinical research offices:
Sanford Bismarck Region: (701) 323-5760
Sanford Fargo Region: (701) 234-2383
Sanford Sioux Falls Region: (605) 328-1368